Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:LUCY NASDAQ:NXGL NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.65+8.7%$0.53$0.31▼$1.80$19.45M-2.646.95 million shs3.52 million shsLUCYInnovative Eyewear$1.98-1.5%$1.97$1.57▼$10.40$6.63M3.18648,279 shs141,469 shsNXGLNexGel$2.67-1.5%$2.45$2.10▼$5.10$21.86M0.5745,845 shs65,419 shsVVOSVivos Therapeutics$3.13-2.2%$3.96$1.98▼$7.95$24.01M6.9495,682 shs104,649 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-20.09%+59.06%+55.13%-37.06%-47.16%LUCYInnovative Eyewear+1.01%+2.55%+13.56%-5.63%-74.23%NXGLNexGel+5.86%+11.98%+22.07%-0.73%+11.07%VVOSVivos Therapeutics+3.23%+0.31%-16.45%-52.02%+32.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.65+8.7%$0.53$0.31▼$1.80$19.45M-2.646.95 million shs3.52 million shsLUCYInnovative Eyewear$1.98-1.5%$1.97$1.57▼$10.40$6.63M3.18648,279 shs141,469 shsNXGLNexGel$2.67-1.5%$2.45$2.10▼$5.10$21.86M0.5745,845 shs65,419 shsVVOSVivos Therapeutics$3.13-2.2%$3.96$1.98▼$7.95$24.01M6.9495,682 shs104,649 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-20.09%+59.06%+55.13%-37.06%-47.16%LUCYInnovative Eyewear+1.01%+2.55%+13.56%-5.63%-74.23%NXGLNexGel+5.86%+11.98%+22.07%-0.73%+11.07%VVOSVivos Therapeutics+3.23%+0.31%-16.45%-52.02%+32.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$7.331,029.77% UpsideLUCYInnovative Eyewear 1.00SellN/AN/ANXGLNexGel 1.00SellN/AN/AVVOSVivos Therapeutics 2.00Hold$4.9257.08% UpsideCurrent Analyst Ratings BreakdownLatest LUCY, FEMY, VVOS, and NXGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LUCYInnovative EyewearWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NXGLNexGelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VVOSVivos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LUCYInnovative EyewearWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NXGLNexGelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VVOSVivos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/9/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.20 ➝ $6.508/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M12.97N/AN/A$0.10 per share6.49LUCYInnovative Eyewear$1.64M3.98N/AN/A$3.72 per share0.53NXGLNexGel$8.69M2.48N/AN/A$0.90 per share2.97VVOSVivos Therapeutics$15.03M1.56N/AN/A$1.35 per share2.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.860.00N/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)LUCYInnovative Eyewear-$7.77M-$2.780.00∞N/A-390.70%-79.72%-74.86%11/11/2025 (Estimated)NXGLNexGel-$3.28M-$0.400.00∞N/A-25.02%-49.37%-25.68%11/12/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.680.00N/AN/A-99.49%-232.76%-84.30%11/13/2025 (Estimated)Latest LUCY, FEMY, VVOS, and NXGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025VVOSVivos Therapeutics-$0.39-$0.55-$0.16-$0.55$3.37 million$3.82 million8/14/2025Q2 2025LUCYInnovative Eyewear-$0.77-$0.66+$0.11-$0.66$1.00 million$0.58 million8/12/2025Q2 2025NXGLNexGel-$0.07-$0.09-$0.02-$0.09$3.08 million$2.88 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ALUCYInnovative EyewearN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.030.890.41LUCYInnovative EyewearN/A18.7015.46NXGLNexGel0.161.740.98VVOSVivos Therapeutics1.691.051.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%LUCYInnovative Eyewear0.96%NXGLNexGel2.21%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%LUCYInnovative Eyewear1.66%NXGLNexGel20.55%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableLUCYInnovative Eyewear93.30 million3.24 millionNot OptionableNXGLNexGel108.07 million6.41 millionNot OptionableVVOSVivos Therapeutics1607.50 million7.35 millionOptionableLUCY, FEMY, VVOS, and NXGL HeadlinesRecent News About These CompaniesVivos Therapeutics announces additional data from use of Vivos DNA deviceSeptember 30, 2025 | msn.comVivos Therapeutics Reports Clinical Data Showing Significant Improvement in ADHD and OSA Symptoms in Children Using FDA-Cleared DNA ApplianceSeptember 30, 2025 | quiverquant.comQVivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA DeviceSeptember 30, 2025 | globenewswire.comVivos Therapeutics announces trial results in pediatric OSA treatmentSeptember 17, 2025 | msn.comVivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea TreatmentSeptember 17, 2025 | globenewswire.comVivos Therapeutics’ Earnings Call: Strategic Transition and GrowthAugust 31, 2025 | tipranks.comVivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call TranscriptAugust 22, 2025 | seekingalpha.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2025 Earnings Call TranscriptAugust 21, 2025 | msn.comVivos Reports 7% Sales DropAugust 21, 2025 | aol.comAVivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 20, 2025 | finanznachrichten.deVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdateAugust 19, 2025 | globenewswire.comVivos Therapeutics, Inc. Announces Upcoming Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | quiverquant.comQVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference CallAugust 19, 2025 | globenewswire.comVivos Therapeutics Delays Q2 2025 10-Q FilingAugust 14, 2025 | msn.comVivos Therapeutics Adds to Management Team to Support Expansion and GrowthJuly 30, 2025 | finance.yahoo.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance - MorningstarJuly 2, 2025 | morningstar.comMVivos Therapeutics Inc. (VVOS) Stock Price Today - WSJJuly 2, 2025 | wsj.comVivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral ApplianceJuly 1, 2025 | taiwannews.com.twTVivos Therapeutics stock soars after Medicare approves VidaSleep oral applianceJuly 1, 2025 | in.investing.comVivos Therapeutics Shares Skyrocket After Medicare Greenlights VidaSleep Oral DeviceJuly 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCY, FEMY, VVOS, and NXGL Company DescriptionsFemasys NASDAQ:FEMY$0.65 +0.05 (+8.71%) Closing price 04:00 PM EasternExtended Trading$0.67 +0.02 (+2.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Innovative Eyewear NASDAQ:LUCY$1.98 -0.03 (-1.49%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.02 (+1.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.NexGel NASDAQ:NXGL$2.67 -0.04 (-1.48%) Closing price 03:59 PM EasternExtended Trading$2.68 +0.02 (+0.56%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Vivos Therapeutics NASDAQ:VVOS$3.13 -0.07 (-2.19%) Closing price 04:00 PM EasternExtended Trading$3.15 +0.02 (+0.51%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
